“Efficacy and Safety Outcomes from the MATISSE Phase 3 Trial of Maternal Bivalent RSVpreF Vaccination Among Pregnant Women Vaccinated at 32 to 36 Weeks of Gestation”. Swiss Medical Weekly 156, no. 1 (January 31, 2026): 4711. Accessed February 5, 2026. https://smw.ch/index.php/smw/article/view/4711.